Xinnate Completes Oversubscribed Share Issue of €3.6 million

Lund, Sweden – Xinnate AB today announced the successful completion of an oversubscribed share issue, driven by strong participation from both existing and new investors. The financing reflects continued confidence in the company’s clinical progress and long-term strategy, including the recently communicated FDA IND approval for TCP-25.

“The strong interest in this share issue underscores investor confidence in our progress and long-term potential,” said Helene Hartman, CEO of Xinnate. “With this support, we are well positioned to advance TCP-25 into Phase 2/3 and execute the next stage of development.”

The newly raised capital will accelerate key development activities for TCP-25, including:

• Executing and expanding the Phase 2/3 study with Epidermolysis Bullosa (EB) patients. The first European sites are just activated and U.S. sites enabled through the recent IND.
• Following advice from FDA, upgrading the study design to potentially serve as the basis of registration upon successful completion.
• Advancing product development and manufacturing.
• Supporting regulatory preparations and authority interactions

The multisite Phase 2/3 study (The STEP study) in DEB and JEB patients is now fully funded through the first half of 2027, when study results are expected.

Xinnate continues to actively engage with commercial partners to support global development and maximize the commercial potential of TCP-25 within the rare-disease and dermatology markets.
 

For more information, please contact: 
Helene Hartman, CEO
helene.hartman@xinnate.com

About Xinnate AB
Xinnate is a clinical-stage pharmaceutical company pioneering novel therapies based on proprietary peptide technology. These therapies aim to address dysfunctional healing by targeting the interplay of microbial presence and inflammatory responses.

With an ambitious development program, Xinnate is dedicated to transforming the lives of patients with Epidermolysis Bullosa and other inflammatory skin conditions. A three-part Phase 1 study of the first drug candidate, TPC-25 gel, has been completed, including a group of patients with Epidermolysis Bullosa. The STEP study, a phase 2/3 study is planned to start before year end 2025.

Xinnate is a SmiLe Venture Hub member.

www.xinnate.com

---

---